Morgan Stanley Maintains Equal-Weight on Centessa Pharmaceuticals, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $8 to $11.
June 21, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Centessa Pharmaceuticals and raises the price target from $8 to $11.
The raised price target from $8 to $11 by a reputable analyst at Morgan Stanley is a positive signal for investors, indicating potential upside. However, the Equal-Weight rating suggests a balanced view, which may temper the overall impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100